Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Menactra: Meningococcal Polysaccharide Diphtheria Conjugate · 1 trial · 3 indications
Meningococcal serogroups A, C, Y, and W-135 antibody titers were measured by serum bactericidal assay using human complement (SBA-HC)
| Arm | Type | Description |
|---|---|---|
| Menactra® Group 1 | EXPERIMENTAL | Participants aged 2 to \< 4 years |
| Menactra® Group 2 | EXPERIMENTAL | Participants aged 4 to \< 6 years |
| Menactra® Group 3 | ACTIVE_COMPARATOR | Participants aged 6 to \< 11 years |
| Name | Type | Description |
|---|---|---|
| Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate | BIOLOGICAL | 0.5 mL, 2 doses Intramuscular |
Inclusion Criteria : * Aged 2 to \< 11 years on the day of inclusion. * Provision of assent form signed by the subject (depending on age) and informed consent form signed by the parent(s) or another legally acceptable representative. * Subject and parent/legal guardian able to attend all scheduled ...
Menactra is a meningococcal vaccine developed by Sanofi for the prevention of meningitis and meningococcal infection caused by Neisseria meningitidis. It is studied in children and is designed to generate an immune response against meningococcal disease.
Menactra is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer responsible for the clinical program evaluating Menactra in pediatric populations.
Menactra has been evaluated in a Phase 2 clinical trial. The trial, NCT00700635, is completed and enrolled 333 participants. The study was an active-controlled dose comparison conducted in the United States.
Menactra has been studied in one completed clinical trial, NCT00700635, titled Dose Comparison Study of Menactra in US Children. The trial enrolled 333 children aged 2 years and older and included healthy volunteers.
Yes, Menactra and Menactra: Meningococcal Polysaccharide Diphtheria Conjugate refer to the same product. The full name describes the vaccine composition, and Menactra is the shorter brand name used in prescribing and research.